Latest Myelin Stories

Lawrence LeBlond for redOrbit.com - Your Universe Online The painful, debilitating symptoms associated with myelin disorders, such as multiple sclerosis and cerebral palsy, may one day be avoided if new breakthroughs in medical science have anything to say about it. One such breakthrough by a team of scientists at Case Western Reserve School of Medicine (CaseMed) has discovered a technique that directly converts skin cells into a type of brain cells destroyed in patients with these myelin...

Role of cells other than motor neurons much larger than anticipated Johns Hopkins scientists say they have evidence from animal studies that a type of central nervous system cell other than motor neurons plays a fundamental role in the development of amyotrophic lateral sclerosis (ALS), a fatal degenerative disease. The discovery holds promise, they say, for identifying new targets for interrupting the disease's progress. In a study described online in Nature Neuroscience, the...

Brett Smith for redOrbit.com - Your Universe Online According to a report in the journal Nature Genetics, an international team of geneticists has announced the successful sequencing of the sea lamprey genome. The sea lamprey makes for an interesting genetic case from an evolutionary standpoint, being a jawless vertebrate that diverged from jawed vertebrates millions of years ago. “The sea lamprey is a primitive jawless vertebrate that diverged from other jawed vertebrates early in...

Marine Biological Laboratory [ Watch The Video Spinal Cord Regerenation In Sea Lamprey ] Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury Scientists at the Marine Biological Laboratory (MBL) have identified several genes linked to human neurological disorders, including Alzheimer's disease, Parkinson's disease and spinal cord injury, in the sea lamprey, a vertebrate fish whose whole-genome sequence is reported this week in the...

GLEN ALLEN, Va., Jan. 31, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS). The study, conducted by the Company's research partner, The Roskamp Institute, was designed to determine whether anatabine had beneficial effects on the development of experimental autoimmune...

An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows. The compound efficiently crossed the blood-brain barrier, did not increase pain and showed no toxic effects to the animals. "This is a first to have a drug that can be taken orally to produce functional improvement with no toxicity in a rodent model," said Sung Ok Yoon, associate professor of molecular & cellular biochemistry at Ohio State...

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ -- Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb paralysis), prevented inflammation in the brain and spinal column while also protecting against...

Part 1: Overview, progress toward stopping MS. New York, NY (PRWEB) December 27, 2012 MS research continued to advance on many fronts in 2012. This year saw:     The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;     The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;...

Part 2: Overview, Progress Toward Restoring Function and Ending MS NEW YORK, Dec. 27, 2012 /PRNewswire-USNewswire/ -- The National MS Society supported new and ongoing initiatives to propel efforts to restore function to people with MS through its Discovery and Fast Forward research programs. (Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO) PROGRESS TOWARD RESTORING FUNCTION LOST TO MS New studies into the potential of adult skin cells and umbilical cord cells as...

MEQUON, Wis., Dec. 10, 2012 /PRNewswire/ -- ENDECE Neural, LLC (www.endeceneural.com) announced today that the company will be presenting at the 2013 Biotech Showcase in San Francisco, California, January 8th. The ENDECE Neural presentation, to be given by Dr. James Yarger, CEO, will discuss the company's novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS). Currently there are no drugs...